Recent review articles on the management of patients with post-ET myelofibrosis recommend prognostic stratification using a clinical-molecular prognostic model to predict survival [30,31], treatment with a JAK-2 inhibitor agent (ruxolitinib, fedratinib, pacritinib, momelotinib or jaktinib), and early consideration of stem cell transplant, especially for patients in the “low risk” category [11,12,32]. This evidence concerns the gene JAK2 and essential thrombocythemia.